Gufic Biosciences Limited

GUFICBIO

INE742B01025

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:50 2024-05-03 am EDT			5-day change	1st Jan Change
321.5 ^INR	-2.35%		-1.89%	+1.90%

Apr. 25	Gufic Biosciences Limited Approves Reconstitution of Various Committees	CI
Apr. 04	Gufic Biosciences Forms New Wholly-Owned Arm in Dubai	MT

Gufic Biosciences Limited Approves Final Dividend for the Financial Year Ended March 31, 2023

September 30, 2023 at 07:55 am EDT

Gufic Biosciences Limited at its AGM held on September 29, 2023 approved final dividend of INR 0.10 per share for the financial year ended March 31, 2023.

Latest news about Gufic Biosciences Limited

Gufic Biosciences Limited Approves Reconstitution of Various Committees	Apr. 25	CI
Gufic Biosciences Forms New Wholly-Owned Arm in Dubai	Apr. 03	MT
Gufic Biosciences Limited Incorporates Wholly Owned Subsidiary Company in Dubai	Apr. 03	CI
Gufic Biosciences Limited Announces Demise of Shrirang Vaidya, Independent Director, Chairman of Audit Committee and Nomination and Remuneration Committee and Member of Risk Management Committee	Apr. 02	CI
Gufic Biosciences Secures Patent in India	Mar. 14	MT
Transcript : Gufic Biosciences Limited, Q3 2024 Earnings Call, Feb 16, 2024	Feb. 16
Gufic Biosciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 14	CI
Gufic Biosciences Gets New Patent in India	Jan. 31	MT
Gufic Biosciences Forms New Pharmaceutical Subsidiary	Nov. 19	MT
Transcript : Gufic Biosciences Limited, Q2 2024 Earnings Call, Nov 17, 2023	Nov. 17
Gufic Biosciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 09	CI
Lumosa Therapeutics Co., Ltd. Approves the Exclusive Licensing Agreement with Gufic Biosciences for LT1001, A Long-Acting Analgesic Injection	Nov. 09	CI
Gufic Biosciences Limited announced that it has received INR 999.9 million in funding from Motilal Oswal Financial Services Limited	23-10-10	CI
Gufic Biosciences Limited Approves Final Dividend for the Financial Year Ended March 31, 2023	23-09-30	CI
Gufic Biosciences Limited Approves Incorporation of Wholly Owned Subsidiary in Dubai, UAE	23-09-27	CI
Gufic Biosciences Granted Patent for its Invention	23-09-14	MT
Gufic Biosciences Gets Nod from Australian, Brazilian Regulators for Parecoxib Sodium Lyophilized Powder	23-09-11	MT
Gufic Biosciences Limited Receives Approval of TGA, Australia and the National Health Surveillance Agency, Brazil for Parecoxib 40Mg Injection	23-09-11	CI
Gufic Biosciences Limited Proposes Final Dividend for the Financial Year Ended March 31, 2023	23-09-06	CI
Motilal Oswal Financial to Acquire 3% Stake in Gufic Biosciences for INR1 Billion	23-09-01	MT
Gufic Biosciences Limited announced that it expects to receive INR 999.9 million in funding from Motilal Oswal Financial Services Limited	23-08-28	CI
Transcript : Gufic Biosciences Limited, Q1 2024 Earnings Call, Aug 14, 2023	23-08-14
Gufic Biosciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-11	CI
Gufic Biosciences Limited Receives Approval from NMPA, China for Prilocaine API	23-06-16	CI
Gufic Biosciences Limited Receives Approval from the Drug Controller General of India for Both Dalbavancin Api and Formulation	23-05-30	CI

Chart Gufic Biosciences Limited

Duration

Period

More charts

Gufic Biosciences Limited is an India-based company, which is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services. The Company operates through the pharmaceutical segment. It has pharmaceutical products under categories, such as Criti Care, including Doxific, Micafung, Rabol and Tigefic-Plus; Criticare Life, including Ticofic-200 and Gufivan-500; Ferticare, including Puregraf 75IU 3D, Cetrocare 0.25mg 3D and Follicare 150IU 3D; Spark, including Aznee Duo, Eclin, Flabone, Vipro M and Zad G; Herbal, including Bocomo-Forte, Sallaki-Liniment, Zulcer Cap and Smashit tablet, and Aesthaderm, including Prosil, Moiseta Face Wash and Revanox Serum. Its personal care products include StretchNil, Shapers-Natural Feel, Shaper-DryFeel and RollOn. Its products under active pharmaceutical ingredient (API)/bulk drugs include Micafungin, Anidulafungin, Sulconazole and Everolimus. Its Gufic Stridden includes Irvical and Eve.

Sector

Pharmaceuticals

Calendar

2024-05-30 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GUFIC BIOSCIENCES LIMITED	+1.90%	387M
NOVO NORDISK A/S	+21.85%	546B
JOHNSON & JOHNSON	-4.77%	359B
MERCK & CO., INC.	+16.97%	323B
ABBVIE INC.	+5.69%	290B
ASTRAZENECA PLC	+13.68%	234B
NOVARTIS AG	+3.65%	198B
ROCHE HOLDING AG	-11.12%	194B
AMGEN INC.	+8.08%	167B
PFIZER, INC.	-3.40%	157B